Gsk (GSK) Receivables - Other (2016 - 2025)
Gsk (GSK) has 9 years of Receivables - Other data on record, last reported at $1.1 billion in Q4 2024.
- For Q4 2024, Receivables - Other fell 15.19% year-over-year to $1.1 billion; the TTM value through Dec 2024 reached $1.1 billion, down 15.19%, while the annual FY2024 figure was $1.1 billion, 15.72% down from the prior year.
- Receivables - Other reached $1.1 billion in Q4 2024 per GSK's latest filing, down from $1.3 billion in the prior quarter.
- Across five years, Receivables - Other topped out at $1.7 billion in Q4 2021 and bottomed at $1.1 billion in Q4 2024.
- Average Receivables - Other over 5 years is $1.4 billion, with a median of $1.3 billion recorded in 2020.
- Peak YoY movement for Receivables - Other: decreased 24.09% in 2020, then increased 27.08% in 2021.
- A 5-year view of Receivables - Other shows it stood at $1.3 billion in 2020, then grew by 27.08% to $1.7 billion in 2021, then decreased by 15.74% to $1.4 billion in 2022, then dropped by 9.81% to $1.3 billion in 2023, then decreased by 15.19% to $1.1 billion in 2024.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $1.1 billion in Q4 2024, $1.3 billion in Q4 2023, and $1.4 billion in Q4 2022.